1 Min Read
Dec 16 (Reuters) - Aptevo Therapeutics Inc :
* "latest data show combination of Otlertuzumab and bendamustine is well tolerated"
* Aptevo - exploring utility of otlertuzumab in combination with additional CLL therapies to evaluate clinical benefit in distinct CLL patient subgroup
* Aptevo Therapeutics announces publication of phase 2 clinical data for otlertuzumab Source text for Eikon: Further company coverage: